This “Food Allergies - Pipeline Insight, 2024,” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Food Allergies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Food Allergies - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Food Allergies pipeline landscape is provided which includes the disease overview and Food Allergies treatment guidelines. The assessment part of the report embraces, in depth Food Allergies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Food Allergies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Omalizumab: Genentech Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE), which treats asthma and chronic idiopathic urticaria symptoms by limiting the allergic response Label. It inhibits IgE binding to receptors on mast cells and basophils, blocking the IgE-mediated secretion of inflammatory mediators from these cells. Omalizumab, manufactured by Genentech, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids. Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated. In September 2018, a new prefilled syringe formulation of this drug was approved by the FDA. Genentech and Novartis Pharmaceuticals Corporation are working closely with NIAID and the Consortium of Food Allergy Research to start a potentially pivotal study assessing the efficacy and safety of Xolair in multiple food allergies. It is currently being evaluated in the Phase III stage of development for treating Peanut Allergypatients.
Dupilumab: Regeneron Pharmaceuticals Dupilumab is a human monoclonal antibody that is an interleukin-4 (IL-4) receptor alpha antagonist. Dupilumab is designed by Regeneron using Veloc Immune® technology. It is an immunoglobulin G4 subclass human monoclonal antibody that work by blocking the IL-4 and interleukin-13 (IL-13) signalling by binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. It is a potential monotherapy administered subcutaneously to the pedantic patients with peanutallergy.
ADP101: Alladapt Immunotherapeutics ADP101 is a proprietary, standardized, oral immunotherapy drug candidate that is being studied for the treatment of food allergy to one or more foods. ADP101 is formulated to consistently deliver a well-characterized investigational drug product sourced from the most commonly allergenic food groups and designed to be administered as part of a clinically monitored dosing protocol. The goal of oral immunotherapy is to induce a state of clinically meaningful desensitization to food proteins, defined as the absence of moderate or severe allergic reaction following the ingestion of small but potentially dangerous amounts of food. ADP101 is based on an intellectual property estate that includes patents and accompanying clinical data licensed from StanfordUniversity.
This product will be delivered within 1-3 business days.
Geography Covered
- Global coverage
Food Allergies Understanding
Food Allergies: Overview
A food allergy occurs when the body’s immune system sees a certain food as harmful and reacts by causing symptoms. This is an allergic reaction. Foods that cause allergic reactions are allergens. The results of skin prick tests (SPT), IgE total and specific antibodies, and patient histories are not predictive of true food allergy, as they are not able to establish the causal and temporal relationship between the intake of the suspect food and the hypersensitivity reaction. The negative predictive accuracy of a skin prick test weal of < 3mm greater than the negative control is high, usually > 95%, and is strong evidence that the food may be consumed without severe, immediate food-allergic reactions. A positive SPT, even a weal of 3 mm or more, may be clinically irrelevant, as the patient may tolerate the ingested food. SPTs may also remain positive after the development of tolerance to the specific food. The foods to which an individual is allergic should be avoided, as therapeutic intervention (tertiary prevention) in patients with food allergy. It must strike a precautionary equilibrium between the demands of prohibitive measures against allergy care and quality of life. Hypersensitivity reactions are often treated with medications. . Epinephrine is the only medication that is effective for the treatment of anaphylaxis. Additional medicatioons include H1 and H2 antihistamines, corticosteroids, and prostaglandin synthetase inhibitors.Food Allergies - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Food Allergies pipeline landscape is provided which includes the disease overview and Food Allergies treatment guidelines. The assessment part of the report embraces, in depth Food Allergies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Food Allergies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Food Allergies.
- In the coming years, the Food Allergies market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- A detailed portfolio of major pharma players who are involved in fueling the Food Allergies treatment market. Several potential therapies for Food Allergies are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Food Allergies market size in the coming years.
- This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Food Allergies) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Food Allergies Emerging Drugs Chapters
This segment of the Food Allergies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Food Allergies Emerging Drugs
Viaskin Peanut: DBV technologies Investigational Viaskin® Peanut therapeutic treatment is based on epicutaneous immunotherapy, or EPIT™. This potential new class of immunotherapey is designed to work by delivering allergens to the immune system through intact skin using our proprietary Viaskin® technology. For those patients facing potentially life-threatening food allergies, this potential immunotherapy treatment aims to desensitize them to allergens by delivering compounds in small quantities into the outer layers of the skin. The investigational EPIT aims to target specific epidermal dendritic cells, called Langerhans cells. Pre-clinical research has shown that these cells capture antigens and migrate to the lymph node in order to activate the immunesystem.Omalizumab: Genentech Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE), which treats asthma and chronic idiopathic urticaria symptoms by limiting the allergic response Label. It inhibits IgE binding to receptors on mast cells and basophils, blocking the IgE-mediated secretion of inflammatory mediators from these cells. Omalizumab, manufactured by Genentech, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids. Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated. In September 2018, a new prefilled syringe formulation of this drug was approved by the FDA. Genentech and Novartis Pharmaceuticals Corporation are working closely with NIAID and the Consortium of Food Allergy Research to start a potentially pivotal study assessing the efficacy and safety of Xolair in multiple food allergies. It is currently being evaluated in the Phase III stage of development for treating Peanut Allergypatients.
Dupilumab: Regeneron Pharmaceuticals Dupilumab is a human monoclonal antibody that is an interleukin-4 (IL-4) receptor alpha antagonist. Dupilumab is designed by Regeneron using Veloc Immune® technology. It is an immunoglobulin G4 subclass human monoclonal antibody that work by blocking the IL-4 and interleukin-13 (IL-13) signalling by binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. It is a potential monotherapy administered subcutaneously to the pedantic patients with peanutallergy.
ADP101: Alladapt Immunotherapeutics ADP101 is a proprietary, standardized, oral immunotherapy drug candidate that is being studied for the treatment of food allergy to one or more foods. ADP101 is formulated to consistently deliver a well-characterized investigational drug product sourced from the most commonly allergenic food groups and designed to be administered as part of a clinically monitored dosing protocol. The goal of oral immunotherapy is to induce a state of clinically meaningful desensitization to food proteins, defined as the absence of moderate or severe allergic reaction following the ingestion of small but potentially dangerous amounts of food. ADP101 is based on an intellectual property estate that includes patents and accompanying clinical data licensed from StanfordUniversity.
Food Allergies: Therapeutic Assessment
This segment of the report provides insights about the different Food Allergies drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Food Allergies
There are approx. 30+ key companies which are developing the therapies for Food Allergies. The companies which have their Food Allergies drug candidates in the most advanced stage, i.e. preregistration include, DBV technologies.Phases
This report covers around 35+ products under different phases of clinical development like- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Food Allergies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Food Allergies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Food Allergies therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Food Allergies drugs.Food Allergies Report Insights
- Food Allergies Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Food Allergies Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:- How many companies are developing Food Allergies drugs?
- How many Food Allergies drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Food Allergies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Food Allergies therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Food Allergies and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- DBV technologies
- Genentech
- Camallergy
- Novartis Pharmaceuticals
- Prota Therapeutics
- Regeneron Pharmaceuticals
- Astrazeneca
- DBV Technologies
- Aimmune Therapeutics (Nestlé)
- InnoUp Farma
- Cour Pharmaceuticals
- Alladapt Immunotherapeutics
- Vedanta Biosciences
- Siolta Therapeutics
- Aravax
- Intrommune Therapeutics
- GI Innovation
- HAL Allergy
- Xencor
- Blue WillowBiologics
- Mabylon
- Allergy Therapeutics
- ASIT biotech
- ALK
- ASIT biotech
Key Products
- Viaskin Peanut
- Omalizumab
- CA002
- Ligelizumab
- PRT100
- Dupilumab
- Acalabrutinib
- DBV135 (Viaskin Milk)
- AR201
- INP20
- CNP-201
- ADP101
- VE 416
- STMC-103H
- PVX108
- INT301
- GI 301
- HAL-MPE1
- AIMab 7195
- Peanut Allergy Therapeutic Vaccine
- pnt-ASIT+TM
- Peanut program
- Research Programme
This product will be delivered within 1-3 business days.
Table of Contents
1. Report Introduction6. Food Allergies Late Stage Products (Phase-III)7. Food Allergies Mid Stage Products (Phase-II)8. Early Stage Products (Phase-I)9. Pre-clinical Products and Discovery Stage Products10. Inactive Products11. Dormant Products12. Food Allergies Discontinued ProductsDetailed information in the report14. Food Allergies Key Companies15. Food Allergies Key Products17. Food Allergies Unmet Needs18. Food Allergies Future Perspectives19. Food Allergies Analyst Review20. Appendix
2. Food Allergies
3. Food Allergies Current Treatment Patterns
4. Food Allergies - Analytical Perspective
5. Therapeutic Assessment
13. Food Allergies Product Profiles
16. Dormant and Discontinued Products
21. Report Methodology
List of Tables
List of Figures
